Undisclosed OST-tADC / OS Therapies - LARVOL DELTA

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models (ACCESSWIRE) - "OS Therapies...announced positive data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable Antibody Drug Conjugate (tADC) platform. The first therapeutic candidate leverages a folate receptor alpha targeting small molecule combined with hexa-exatecan payloads (OST-tADC-FRA-H) linked together with the Company's proprietary silicone linker technology, SiLinker. The data generated showed strong antitumor activity in the KB and IGROV-1 mouse models of ovarian cancer. Taken together, the data provide compelling preclinical proof of concept that the Company's SiLinker platform can be used to develop new therapeutic tADC-based drug candidates that can improve the safety and/or efficacy of ADC combinations currently on the market or in development..."

Preclinical • Ovarian Cancer

OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX” (Businesswire) - "OS Therapies Incorporated...announced the pricing of its initial public offering of 1,600,000 shares of common stock at a public offering price of $4.00 per share, raising gross proceeds of $6.4 million....The net proceeds, after deducting underwriting discounts and commissions, but before estimated expenses of the offering payable by the Company, are expected to be approximately $6.0 million. The Company intends to use the net proceeds from the offering to advance the clinical development of its product candidates – OST-HER2 and OST-tADC – and discover and develop new product candidates, as well as for working capital and other general corporate purposes."

Financing • Breast Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor